Overview

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD. The clinical hypothesis is that denosumab subcutaneous injections administered every 3 or 6 months for 12 months will significantly increase lumbar spine bone mineral density and will be well tolerated.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Alendronate
Denosumab